TLR4 and cancer: These findings suggest that mygalin can block activation by LPS via TLR4 as with other anti-inflammatory molecules, such as corticosteroids [78], peptides [79], and chalcones (including okanin [80] and others thereby showing that thispathway has therapeutic potential for different inflammatory diseases and cancers) [80].